Report workspace tools

NCT00005901COMPLETEDanonymous

A Trial of Pamidronate in Children With Osteogenesis Imperfecta

Sponsor

Source record

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

Pamidronate (Aredia)

Indication / condition

AI-normalized

Osteogenesis Imperfecta

Intervention

Source record

Pamidronate (Aredia)

Source & freshness

Source record

NCT ID

NCT00005901

Original source

ClinicalTrials.gov

Source last updated

Mar 01, 2016

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00005901

Title

A Trial of Pamidronate in Children With Osteogenesis Imperfecta

Sponsor

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Status

COMPLETED

Phase

PHASE3

Condition raw

Osteogenesis Imperfecta

Condition normalized

Osteogenesis Imperfecta

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Pamidronate (Aredia)

Target normalized

Pamidronate (Aredia)

Interventions

Pamidronate (Aredia)

Public preview

Source record

This study will evaluate the effect of pamidronate a drug that decreases bone resorption (breakdown) on osteogenesis imperfecta. This is a genetic disorder of collagen, the major protein in bone. The abnormal collagen causes weak bones, and children with severe osteogenesis imperfecta sustain many fractures throughout their lives. They also have growth deficiency, curvature of the spine, crumbling teeth, hearing loss, easy bruising and heart and lung problems. The study will compare bone density, quality and strength, final adult height, trunk height, and functional ability in children who receive 1) pamidronate every 3 months, 2) pamidronate every 3 months + growth hormone injections, 3) pamidronate every 6 months, or 4) pamidronate every 6 months + growth hormone injections.

Children 2 years of age and older with severe osteogenesis imperfecta (types III and IV) may be eligible for this study. Those enrolled will be randomly assigned to groups according to age; children two to four years of age will be randomly assigned to receive pamidronate every 3 or every 6 months. Children four years of age and older may participate in the growth hormone treatment groups. These children will continue on growth hormone until they reach their adult height or fail to grow as much as would be expected for someone on growth hormone.

Patients will be followed in the clinic every 3 months for a history, physical examination, X-rays, blood tests, and measurements (weight, head circumference, and bone lengths). Children will receive a 3 to 4 hour infusion of pamidronate through an intravenous catheter (thin flexible tube placed in a vein) once a day for 3 days each visit. (Once inserted, the catheter is left in place to avoid multiple needle sticks for administering the drug and collecting blood samples.) Children who are taking growth hormone will be given the drug at the first treatment visit. At that time, the accompanying parent will be instructed on how to mix the drug and give injections. The child receives an injection 6 days a week (Sunday off).

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account

Create a free account first, then unlock a single report, buy credits or subscribe.